Bassam Awwa, MD | |
41 Fair Harbour Pl, New London, CT 06320-4710 | |
(860) 437-6914 | |
(860) 437-6920 |
Full Name | Bassam Awwa |
---|---|
Gender | Male |
Speciality | Psychiatry |
Experience | 47 Years |
Location | 41 Fair Harbour Pl, New London, Connecticut |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1881774354 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 24399 (Connecticut) | Secondary |
2084P0800X | Psychiatry & Neurology - Psychiatry | 024399 (Connecticut) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Connecticut Behavioral Health Assoc, P.c. | 4385532373 | 35 |
News Archive
Short-term exposure to most major air pollutants appears to increase the risk of being hospitalised for and dying from heart failure, according to a systematic review and meta-analysis of data from 12 countries published in The Lancet.
A new study finds companies with healthy workforces appear to have a competitive edge in the stock market. The study compared the stock market performance of ten of the healthiest companies in South Africa to the market at large. Nine different investment scenarios were tested and, in all nine scenarios, the healthy companies outperformed the Johannesburg Stock Exchange All Share Index.
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
› Verified 9 days ago
Entity Name | Connecticut Behavioral Health Assoc, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629158126 PECOS PAC ID: 4385532373 Enrollment ID: O20040310000567 |
News Archive
Short-term exposure to most major air pollutants appears to increase the risk of being hospitalised for and dying from heart failure, according to a systematic review and meta-analysis of data from 12 countries published in The Lancet.
A new study finds companies with healthy workforces appear to have a competitive edge in the stock market. The study compared the stock market performance of ten of the healthiest companies in South Africa to the market at large. Nine different investment scenarios were tested and, in all nine scenarios, the healthy companies outperformed the Johannesburg Stock Exchange All Share Index.
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Bassam Awwa, MD 41 Fair Harbour Pl, New London, CT 06320-4710 Ph: (860) 437-6914 | Bassam Awwa, MD 41 Fair Harbour Pl, New London, CT 06320-4710 Ph: (860) 437-6914 |
News Archive
Short-term exposure to most major air pollutants appears to increase the risk of being hospitalised for and dying from heart failure, according to a systematic review and meta-analysis of data from 12 countries published in The Lancet.
A new study finds companies with healthy workforces appear to have a competitive edge in the stock market. The study compared the stock market performance of ten of the healthiest companies in South Africa to the market at large. Nine different investment scenarios were tested and, in all nine scenarios, the healthy companies outperformed the Johannesburg Stock Exchange All Share Index.
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
› Verified 9 days ago
Bilal Hameed, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 194 Howard St Ste 1, New London, CT 06320 Phone: 860-440-0640 Fax: 860-865-2397 | |
Dr. Sherrie Sharp, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 255 Hempstead St, New London, CT 06320 Phone: 860-443-2896 | |
Dr. Henry F Crabbe, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5 Shaws Cv Ste 207, New London, CT 06320 Phone: 860-444-8877 Fax: 860-444-9660 | |
Dr. Louis Henry Reich, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 292 Montauk Avenue, New London, CT 06320 Phone: 860-443-1200 Fax: 860-442-4488 | |
Dr. Stephen Glenn Vance, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 21 Montauk Ave, New London, CT 06320 Phone: 860-439-6400 Fax: 860-271-4797 | |
Dr. Ammar S Traboulsi, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 41 Fair Harbour Pl, New London, CT 06320 Phone: 860-437-6914 | |
Amy Stevens, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 365 Montauk Ave, New London, CT 06320 Phone: 860-271-4655 |